Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase II clinical trial for the treatment of hospitalized COVID-19 patients; and phase II clinical trial for the treatment of COVID-19. In addition, the company is developing R835, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trial for autoimmune, inflammatory, and hematology-oncology diseases; and R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor that has completed phase I clinical trial for autoimmune and inflammatory diseases. It has research and license agreements with Aclaris Therapeutics International Limited for the development and commercialization of janus kinase (JAK) inhibitors for the treatment of alopecia areata and other dermatological conditions; AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Fostamatinib. The company also has a license agreement and strategic collaboration with Eli Lilly and Company to co-develop and commercialize R552 for various indications, including autoimmune and inflammatory diseases, as well as other non-central nervous system (non-CNS) disease development candidates. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.
IPO Year: 2000
Exchange: NASDAQ
Website: rigel.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/3/2023 | $2.00 | Neutral | Piper Sandler |
| 6/9/2022 | Buy → Neutral | Citigroup | |
| 6/8/2022 | $7.00 → $1.00 | Overweight → Neutral | Piper Sandler |
| 6/8/2022 | $6.00 → $1.00 | Overweight → Neutral | Cantor Fitzgerald |
| 3/23/2022 | $4.00 | Neutral | B. Riley Securities |
Preliminary fourth quarter 2024 total revenue of approximately $57.6 million which includes TAVALISSE® net product sales of $31.0 million, REZLIDHIA® net product sales of $7.4 million and GAVRETO® net product sales of $8.1 million R289 granted Orphan Drug designation by the FDA for the treatment of MDSRigel anticipates 2025 total revenue of approximately $200 to $210 millionSOUTH SAN FRANCISCO, Calif., Jan. 13, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today provided a business update including preliminary total revenue and net product sales for the fourth quarter of 2024, ongoing acti
SOUTH SAN FRANCISCO, Calif., Jan. 9, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to R289 for the treatment of myelodysplastic syndromes (MDS). R2891, Rigel's potent and selective dual inhibitor of IRAK1 and IRAK4, is being studied in an ongoing Phase 1b study evaluating the safety, tolerability, pharmacokinetics and preliminary activity in patients with LR-MDS who are relapsed or refractory to prior therapies. "Receiving Orphan Drug designation for R289 supports the development of this th
SOUTH SAN FRANCISCO, Calif., Jan. 8, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Raul Rodriguez, the company's president and CEO, will present a company overview at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2025 at 8:15 a.m. PT (11:15 a.m. ET) in San Francisco, CA. To access the live webcast or archived recording, visit the Investor Relations section of the company's website at www.rigel.com. Please connect to Rigel's website prior to the start of the live webcast to allow for any software downloads. About RigelRigel Pharmaceuticals,
SOUTH SAN FRANCISCO, Calif., Jan. 3, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (NASDAQ:RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and granted as an inducement material to employees' entering into employment with Rigel, in accordance with NASDAQ Listing Rule 5635(c)(4). Specifically, Rigel granted 46,131 stock options to eight non-executive employees vesting over four years with a one-year cliff. About RigelRigel Pharmaceuticals, Inc. (NASDAQ:RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies t
R289 was generally well tolerated and demonstrated signs of preliminary clinical activity in elderly heavily pretreated LR-MDS patientsRBC-TI/HI-E responses occurred in 40% of evaluable TD patients receiving R289 doses ≥500 mg QDSOUTH SAN FRANCISCO, Calif., Dec. 9, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced initial data from its ongoing Phase 1b study evaluating R2891, an oral prodrug of R835, a potent and selective dual inhibitor of IRAK1 and IRAK4, in patients with relapsed or refractory (R/R) lower-risk myelodysplastic syndrome (LR-MDS). The data is being presented to
SOUTH SAN FRANCISCO, Calif., Dec. 2, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to R289 for the treatment of patients with previously-treated transfusion dependent lower-risk myelodysplastic syndrome (LR-MDS). R2891, Rigel's potent and selective dual inhibitor of IRAK1 and IRAK4, is being studied in an ongoing Phase 1b study evaluating the safety, tolerability, pharmacokinetics and preliminary activity in patients with LR-MDS who are relapsed or refractory to prior therapies. "We are plea
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Dean Schorno, the company's chief financial officer, will present a company overview at the Jefferies London Healthcare Conference on Tuesday, November 19, at 9:30 am GMT (4:30 am EST). To access the live webcast or archived recording, visit the Investor Relations section of the company's website at www.rigel.com. Please connect to Rigel's website prior to the start of the live webcast to allow for any software downloads. About RigelRigel Pharmaceuticals, Inc. (NASDAQ:RIGL) is a biotech
Third quarter total revenue of $55.3 million, which includes TAVALISSE® net product sales of $26.3 million, REZLIDHIA® net product sales of $5.5 million and GAVRETO® net product sales of $7.1 million Entered into an agreement with Kissei to develop and commercialize REZLIDHIA in all potential indications in Japan, the Republic of Korea and Taiwan, recording an upfront cash payment of $10.0 million during the third quarterInitial data from the ongoing Phase 1b study evaluating R289, a dual IRAK1/4 inhibitor, in LR-MDS to be presented at the 66th ASH Annual MeetingConference call and webcast scheduled today at 4:30 p.m. Eastern TimeSOUTH SAN FRANCISCO, Calif., Nov. 7, 2024 /PRNewswire/ -- Rige
- Initial data from the ongoing Phase 1b study evaluating R289, a dual IRAK1/4 inhibitor, in LR-MDS- Additional data for REZLIDHIA® (olutasidenib) in patients with mIDH1 AML and MDS SOUTH SAN FRANCISCO, Calif., Nov. 5, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced upcoming presentations of six posters highlighting data from their commercial and clinical-stage hematology-oncology portfolio at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition being held December 7-10, 2024, in San Diego, California and virtually. Rigel's presentations will incl
SOUTH SAN FRANCISCO, Calif., Oct. 31, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) today announced that it will report its third quarter 2024 financial results after market close on Thursday, November 7, 2024. Rigel senior management will follow the announcement with a live conference call and webcast at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results and give an update on the business. Participants can access the live conference call by dialing 877-407-3088 (domestic) or 201-389-0927 (international). The conference call and accompanying slides will also be webcast live and can be accessed from the Investor Relations section of the company's
Preliminary fourth quarter 2024 total revenue of approximately $57.6 million which includes TAVALISSE® net product sales of $31.0 million, REZLIDHIA® net product sales of $7.4 million and GAVRETO® net product sales of $8.1 million R289 granted Orphan Drug designation by the FDA for the treatment of MDSRigel anticipates 2025 total revenue of approximately $200 to $210 millionSOUTH SAN FRANCISCO, Calif., Jan. 13, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today provided a business update including preliminary total revenue and net product sales for the fourth quarter of 2024, ongoing acti
Third quarter total revenue of $55.3 million, which includes TAVALISSE® net product sales of $26.3 million, REZLIDHIA® net product sales of $5.5 million and GAVRETO® net product sales of $7.1 million Entered into an agreement with Kissei to develop and commercialize REZLIDHIA in all potential indications in Japan, the Republic of Korea and Taiwan, recording an upfront cash payment of $10.0 million during the third quarterInitial data from the ongoing Phase 1b study evaluating R289, a dual IRAK1/4 inhibitor, in LR-MDS to be presented at the 66th ASH Annual MeetingConference call and webcast scheduled today at 4:30 p.m. Eastern TimeSOUTH SAN FRANCISCO, Calif., Nov. 7, 2024 /PRNewswire/ -- Rige
SOUTH SAN FRANCISCO, Calif., Oct. 31, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) today announced that it will report its third quarter 2024 financial results after market close on Thursday, November 7, 2024. Rigel senior management will follow the announcement with a live conference call and webcast at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results and give an update on the business. Participants can access the live conference call by dialing 877-407-3088 (domestic) or 201-389-0927 (international). The conference call and accompanying slides will also be webcast live and can be accessed from the Investor Relations section of the company's
Second quarter total revenue of $36.8 million, which includes TAVALISSE® net product sales of $26.4 million, REZLIDHIA® net product sales of $5.2 million and GAVRETO® net product sales of $1.9 millionSuccessfully completed NDA transfer of GAVRETO for the treatment of RET fusion-positive metastatic non-small cell lung cancer and advanced or metastatic thyroid cancer, with product available from Rigel beginning June 27, 2024Conference call and webcast scheduled today at 4:30 p.m. Eastern TimeSOUTH SAN FRANCISCO, Calif., Aug. 6, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today reported fin
SOUTH SAN FRANCISCO, Calif., July 30, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) today announced that it will report its second quarter 2024 financial results after market close on Tuesday, August 6, 2024. Rigel senior management will follow the announcement with a live conference call and webcast at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results and give an update on the business. Participants can access the live conference call by dialing 877-407-3088 (domestic) or 201-389-0927 (international). The conference call and accompanying slides will also be webcast live and can be accessed from the Investor Relations section of the company's w
First quarter 2024 total revenue of $29.5 million, which includes TAVALISSE® net product sales of $21.1 million and REZLIDHIA® net product sales of $4.9 millionExpanded Rigel's portfolio with acquisition of GAVRETO®, a U.S. marketed product for RET fusion-positive metastatic non-small cell lung cancer and advanced or metastatic thyroid cancerAppointed Lisa Rojkjaer, M.D. as Chief Medical OfficerConference call and webcast scheduled today at 4:30 p.m. Eastern TimeSOUTH SAN FRANCISCO, Calif., May 7, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) today reported financial results for the first quarter ended March 31, 2024, including sales of TAVALISSE® (fostamatinib disodium hexa
SOUTH SAN FRANCISCO, Calif., April 30, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) today announced that it will report its first quarter 2024 financial results after market close on Tuesday, May 7, 2024. Rigel senior management will follow the announcement with a live conference call and webcast at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results and give an update on the business. Participants can access the live conference call by dialing 877-407-3088 (domestic) or 201-389-0927 (international). The conference call and accompanying slides will also be webcast live and can be accessed from the Investor Relations section of the company's webs
Fourth quarter 2023 Total Revenue of $35.8 million which includes TAVALISSE® net product sales of $25.7 million and REZLIDHIA® net product sales of $3.9 millionExpanded product portfolio with acquisition of U.S. rights to GAVRETO®, an FDA approved targeted therapy for the treatment of RET fusion-positive metastatic non-small cell lung cancer and advanced or metastatic thyroid cancer Conference call and webcast scheduled today at 4:30 p.m. Eastern TimeSOUTH SAN FRANCISCO, Calif., March 5, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) today reported financial results for the fourth quarter and full year ended December 31, 2023, including sales of TAVALISSE® (fostamatinib disod
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) today announced that it will report its fourth quarter and full year 2023 financial results after market close on Tuesday, March 5, 2024. Rigel senior management will follow the announcement with a live conference call and webcast at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results and give an update on the business. Participants can access the live conference call by dialing 877-407-3088 (domestic) or 201-389-0927 (international). The conference call and accompanying slides will also be webcast live and can be accessed from the Investor Relations section of th
GAVRETO® (pralsetinib) is an FDA approved targeted therapy for the treatment of RET fusion-positive metastatic non-small cell lung cancer and advanced or metastatic thyroid cancer Acquisition of established U.S. marketed product further expands Rigel's portfolio and leverages Rigel's existing infrastructure in both the institutional and community settingsGAVRETO generated ~$28M in U.S. net product sales in 2023SOUTH SAN FRANCISCO, Calif., Feb. 22, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (NASDAQ:RIGL) today announced that it has entered into a definitive agreement to acquire the U.S. rights to GAVRETO® (pralsetinib) from Blueprint Medicines Corporation ("Blueprint"). GAVRET
4 - RIGEL PHARMACEUTICALS INC (0001034842) (Issuer)
4 - RIGEL PHARMACEUTICALS INC (0001034842) (Issuer)
4 - RIGEL PHARMACEUTICALS INC (0001034842) (Issuer)
4 - RIGEL PHARMACEUTICALS INC (0001034842) (Issuer)
4 - RIGEL PHARMACEUTICALS INC (0001034842) (Issuer)
4 - RIGEL PHARMACEUTICALS INC (0001034842) (Issuer)
4 - RIGEL PHARMACEUTICALS INC (0001034842) (Issuer)
4 - RIGEL PHARMACEUTICALS INC (0001034842) (Issuer)
4 - RIGEL PHARMACEUTICALS INC (0001034842) (Issuer)
4 - RIGEL PHARMACEUTICALS INC (0001034842) (Issuer)
SC 13G/A - RIGEL PHARMACEUTICALS INC (0001034842) (Subject)
SC 13G/A - RIGEL PHARMACEUTICALS INC (0001034842) (Subject)
SC 13G - RIGEL PHARMACEUTICALS INC (0001034842) (Subject)
SC 13G/A - RIGEL PHARMACEUTICALS INC (0001034842) (Subject)
SC 13G - RIGEL PHARMACEUTICALS INC (0001034842) (Subject)
SC 13G/A - RIGEL PHARMACEUTICALS INC (0001034842) (Subject)
SC 13G/A - RIGEL PHARMACEUTICALS INC (0001034842) (Subject)
SC 13G/A - RIGEL PHARMACEUTICALS INC (0001034842) (Subject)
SC 13G - RIGEL PHARMACEUTICALS INC (0001034842) (Subject)
SC 13G - RIGEL PHARMACEUTICALS INC (0001034842) (Subject)
8-K - RIGEL PHARMACEUTICALS INC (0001034842) (Filer)
8-K - RIGEL PHARMACEUTICALS INC (0001034842) (Filer)
8-K - RIGEL PHARMACEUTICALS INC (0001034842) (Filer)
10-Q - RIGEL PHARMACEUTICALS INC (0001034842) (Filer)
8-K - RIGEL PHARMACEUTICALS INC (0001034842) (Filer)
8-K - RIGEL PHARMACEUTICALS INC (0001034842) (Filer)
EFFECT - RIGEL PHARMACEUTICALS INC (0001034842) (Filer)
S-8 - RIGEL PHARMACEUTICALS INC (0001034842) (Filer)
8-K - RIGEL PHARMACEUTICALS INC (0001034842) (Filer)
10-Q - RIGEL PHARMACEUTICALS INC (0001034842) (Filer)
SOUTH SAN FRANCISCO, Calif., March 12, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) today announced the appointment of Lisa Rojkjaer, M.D. as Executive Vice President and Chief Medical Officer. Dr. Rojkjaer is an industry veteran with over 20 years of clinical development, regulatory, and medical affairs experience with a focus on hematology and oncology. She is a board-certified hematologist with an international clinical practice background. "It is a pleasure to welcome Lisa to the team. She brings to Rigel a strong combination of industry leadership experience paired with drug development and regulatory affairs expertise. Her robust hematology and oncology knowledge comp
STAMFORD, Conn., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the appointment of Ryan Maynard as Chief Financial Officer (CFO), effective immediately. As a member of the Executive Leadership Team, Mr. Maynard will lead the Company's financial operations. "Ryan's deep financial leadership experience will be instrumental to the execution of Cara's long-term growth strategy as we continue to maximize the KORSUVA™ (difelikefalin) injection launch and advance our oral difelikefalin pipeline to establish our position
SOUTH SAN FRANCISCO, Calif., Dec. 16, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) today announced that it has appointed Kamil Ali-Jackson to the company's Board of Directors. Ms. Ali-Jackson brings nearly four decades of biopharmaceutical industry experience to Rigel, including expertise in negotiating licensing, joint-venture, and M&A transactions to drive strategic growth. "Kamil is a savvy businessperson, has a sharp transactional mind, and is a serial entrepreneur who brings immense experience to our board," said Raul Rodriguez, president and CEO of Rigel. "Her experience as an international transaction attorney, litigator, biotech founder, and pharmaceutical executi
Piper Sandler resumed coverage of Rigel Pharma with a rating of Neutral and set a new price target of $2.00
Citigroup downgraded Rigel Pharma from Buy to Neutral
Piper Sandler downgraded Rigel Pharma from Overweight to Neutral and set a new price target of $1.00 from $7.00 previously
Cantor Fitzgerald downgraded Rigel Pharma from Overweight to Neutral and set a new price target of $1.00 from $6.00 previously
B. Riley Securities initiated coverage of Rigel Pharma with a rating of Neutral and set a new price target of $4.00
HC Wainwright resumed coverage of Rigel Pharmaceuticals with a rating of Buy and set a new price target of $11.00
HC Wainwright reiterated coverage of Rigel Pharmaceuticals with a rating of Buy and set a new price target of $11.00 from $8.00 previously
HC Wainwright reiterated coverage of Rigel Pharmaceuticals with a rating of Buy and set a new price target of $11.00 from $8.00 previously